ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Allogene Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.30−0.01 (-0.76%)
Close on Oct 19, 2026
- Market cap
- $427.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -38.5% | -53.4% | |
| Return on assets | – | -32.5% | -39.6% | |
| Current ratio | – | 8.96 | 7.93 | |
| Interest coverage | – | – | -194.7× | |
| Capex to revenue | – | – | – | |
| Diluted shares | – | 120M | 221M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Allogene Therapeutics generated $992.61M from operations and spent $29.23M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$992.61M
Used
$29.23M
Capital expenditure$29.23M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1170863.6%
×Asset turnover0.00×
×Equity multiplier1.28×
=Return on equity, FY2024-55.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -1170863.6% | 0.00× | 1.28× | -55.1% |
| FY2023 | -344489.5% | 0.00× | 1.24× | -55.5% |
| FY2022 | -218214.1% | 0.00× | 1.18× | -42.8% |
| FY2021 | -159.6% | 0.10× | 1.18× | -18.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$190.89M
- Cash generatingOperating cash flow above zero-$149.25M
- Return on assets improvedROA up on the prior year-40.1% → -34.8%
- Earnings backed by cashOperating cash flow above net income-$149.25M vs -$190.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.54 → 7.93
- No dilutionShare count did not rise195M → 221M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00